All In Biotech

Drug Trial Radar · NCT04961996

A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Patients With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 4,170 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

4,170

Actual

Start

Aug 27, 2021

Primary completion

Aug 8, 2025

Study completion Sep 30, 2033

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Jul 14, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with physician's choice of endocrine therapy in participants with medium- and high-risk Stage I-III histologically confirmed estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative early breast cancer.

Conditions

  • Early Breast Cancer

Interventions

  • GiredestrantDrug

    Giredestrant 30 milligrams (mg) will be administered orally once a day (QD) on Days 1-28 of each 28-day cycle for 5 years or until disease recurrence or unacceptable toxicity (whichever occurs first).

  • Physician's Choice of Endocrine TherapyDrug

    The physician's choice of endocrine therapy (PCET) is limited to tamoxifen or one of the specified third generation aromatase inhibitors: letrozole, anastrozole, or exemestane. Participants will receive PCET daily on Days 1-28 of each 28-day cycle for 5 years or until disease recurrence or unacceptable toxicity (whichever occurs first). Continuing PCET after 5 years is at the discretion of the investigator and per local standard of care. Dose administration of PCET should be performed in accordance with the local prescribing information for the respective product.

  • LHRH AgonistDrug

    A luteinizing hormone-releasing hormone (LHRH) agonist will be administered to male participants and premenopausal/perimenopausal participants according to local prescribing information. LHRH agonists may include, but are not limited to, leuprolide acetate, goserelin acetate, or triptorelin pamoate. The investigator may determine and supply the appropriate LHRH agonist locally approved for use in breast cancer.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Invasive Disease-Free Survival (IDFS), Excluding Second Primary Non-Breast CancersTime frame: From randomization to first occurrence of an IDFS event (up to 10 years)

Locations

621 sites in 54 countries. Site status is shown where the registry gives one.

  • Southern Cancer Center

    Daphne, Alabama

  • CBCC Global Research Inc., at Comprehensive Blood and Cancer Center

    Bakersfield, California

  • St Joseph Heritage Healthcare

    Fullerton, California

  • Long Beach Memorial Medical Center

    Long Beach, California

  • Cancer and Blood Specialty Clinic-California-Katella Ave

    Los Alamitos, California

  • The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange

    Orange, California

  • Kaiser Permanente - San Diego

    San Diego, California

  • Sansum Clinic

    Santa Barbara, California

  • UCLA Hematology/Oncology

    Santa Monica, California

  • Torrance Memorial Physician Network/Cancer Care

    Torrance, California

  • Kaiser Permanente - Vallejo

    Vallejo, California

  • Rocky Mountain Cancer Centers (Longmont) - USOR

    Longmont, Colorado

  • Stamford Hospital

    Stamford, Connecticut

  • Memorial Healthcare System - Memorial Regional Hospital

    Hollywood, Florida

  • Baptist - MD Anderson Cancer Center

    Jacksonville, Florida

  • Mount Sinai Comprehensive Cancer Center

    Miami Beach, Florida

  • University of Chicago Hospital

    Chicago, Illinois

  • Duly Health and Care

    Tinley Park, Illinois

  • Cancer Center of Kansas - Kingman

    Kingman, Kansas

  • University of Kentucky

    Lexington, Kentucky

  • Norton Cancer Institute - MDC

    Louisville, Kentucky

  • Hematology/Oncology Clinic, LLP

    Baton Rouge, Louisiana

  • University Medical Center New Orleans

    New Orleans, Louisiana

  • University of Maryland

    Towson, Maryland

  • Lahey Clinic Med Ctr

    Burlington, Massachusetts

  • Massachusetts General Hospital

    Lexington, Massachusetts

  • University Of Michigan

    Ann Arbor, Michigan

  • Metro-Minnesota Community Oncology Research Consortium

    Saint Louis Park, Minnesota

  • University of Missouri-Columbia

    Columbia, Missouri

  • St. Vincent Frontier Cancer Center

    Billings, Montana

  • Nebraska Cancer Specialists

    Omaha, Nebraska

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • Hunterdon Hematology Oncology

    Flemington, New Jersey

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

  • New York University Cancer Cen

    New York, New York

  • Stony Brook Univ Cancer Ctr

    Stony Brook, New York

  • Messino Cancer Centers

    Asheville, North Carolina

  • Rex Cancer Center

    Raleigh, North Carolina

  • Atrium Health Wake Forest Baptist Medical Center - PPDS

    Winston-Salem, North Carolina

  • Aultman Hospital

    Canton, Ohio

Showing 40 of 621 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.